| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | nelarabine | CTRPv2 | pan-cancer | AAC | 0.36 | 9e-18 |
| mRNA | barasertib | CTRPv2 | pan-cancer | AAC | 0.27 | 8e-14 |
| mRNA | ABT-263 | CTRPv2 | pan-cancer | AAC | 0.29 | 3e-13 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | 0.21 | 2e-11 |
| mRNA | PD-0325901 | GDSC1000 | pan-cancer | AAC | -0.24 | 3e-11 |
| mRNA | GSK1070916 | GDSC1000 | pan-cancer | AAC | 0.23 | 5e-11 |
| mRNA | PX-12 | CTRPv2 | pan-cancer | AAC | 0.21 | 6e-11 |
| mRNA | decitabine:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.22 | 2e-10 |
| mRNA | RG-108 | CTRPv2 | pan-cancer | AAC | 0.26 | 2e-10 |
| mRNA | ABT-737 | CTRPv2 | pan-cancer | AAC | 0.26 | 3e-10 |